CTNI-51. NEUROCOGNITIVE FUNCTION (NCF) OUTCOMES OF RTOG FOUNDATION 3508: A PHASE 3 TRIAL OF ABT-414 WITH CONCURRENT CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE IN PATIENTS WITH EGFR-AMPLIFIED NEWLY DIAGNOSED GBM

RTOG 3508/AbbVie M13-813/INTELLANCE-1 was a phase 3 trial of depatuximab-mafodotin (depatux-m, formerly ABT-414) that accrued 639 patients with EGFR-amplified newly diagnosed GBM. At the pre-specified interim OS analysis, the futility criteria were met and there was no survival benefit from adding d...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Neuro Oncol
Autori principali: Wefel, Jeffrey S, Won, Minhee, Lassman, Andrew, Stern, Yaakov, Wang, Tony, Aldape, Kenneth, Armstrong, Terri, Vogelbaum, Michael, Sulman, Erik, Moazami, Golnaz, Macsai, Marian, Gilbert, Mark, Bain, Earle, Blot, Vincent, Gan, Hui, Preusser, Matthias, Ansell, Peter, Samanta, Suvajit, Kundu, Madan, Seidel, Clemens, de Vos, Filip, Hsu, Sigmund, Cardona, Andres, Lombardi, Giuseppe, Bentsion, Dmitry, Peterson, Richard, Gedye, Craig, Lebrun-Frenay, Christine, Wick, Antje, Pugh, Stephanie, Curran, Walter, Mehta, Minesh
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2020
Soggetti:
Clinical Trials: Non-Immunologic
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650869/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.217
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi